Advertisement

Wiener klinische Wochenschrift

, Volume 125, Issue 15–16, pp 481–486 | Cite as

Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study

  • Marco Ronald Hassler
  • Wolfgang Pfeifer
  • Thomas Hendrik Knocke-Abulesz
  • Klaus Geissler
  • Gabriele Altorjai
  • Karin Dieckmann
  • Christine MarosiEmail author
original article

Summary

Background

This multicentric randomized phase II study investigated the feasibility and toxicity of temozolomide (TMZ) added to whole brain radiotherapy (WBRT) followed by adjuvant TMZ in patients with multiple brain metastases of non-small-cell lung cancer (NSCLC).

Methods

Patients with multiple brain metastases from NSCLC aged ≥ 18 years, classified according to recursive partitioning analysis class I or II and with adequate organ functions were eligible. Treatment consisted of WBRT + TMZ 75 mg/m2 for 2 weeks followed at day 28 by TMZ 100 mg/m2/day 2 weeks on/2 weeks off for up to 6 months (radiochemotherapy, RCT) or WBRT alone (radiotherapy, RT).

Results

The study enrolled only 35 patients (22 patients in RCT and 13 in RT) and had to be closed prematurely due to poor accrual. The toxicity was mainly due to TMZ with WHO grade 3 and 4 thrombocytopenia in 3/22 versus 0/13, leucocytopenia in 1/22 versus 0/13 and lymphocytopenia in 7/22 versus 12/13 patients in RCT and RT respectively. Thirteen patients in RCT and six in RT progressed systemically and dropped out before first restaging of the response in brain. Median time to progression (TTP) was 2.4 months (95 % CI: 2–2.6 months) and 2.0 months (95 % CI: 0.5–3.5 months), median overall survival (OAS) was 3 months (95 % CI: 1.7–3.1 months) and 6.3.months (95 % CI: 0.2–7.6 months) in RCT and RT, respectively.

Conclusions

Like other studies before on patients with brain metastases, insufficient number of recruited patients does not allow conclusions on efficacy and toxicity as the study closed prematurely.

Keywords

Brain metastases Non-small-cell lung cancer Whole brain radiotherapy Temozolomide Trial design 

Radiochemotherapie mit Temozolomid für Patienten mit Hirnmetastasen bei nicht kleinzelligem Lungenkarzinom

Zusammenfassung

Grundlagen Wir berichten über die Ergebnisse einer multizentrischen randomisierten österreichischen Phase II Studie über Verträglichkeit und Toxizität der Zugabe von Temozolomid (TMZ) zur Ganzhirnbestrahlung (WBRT) bei PatientInnen mit multiplen Hirnmetastasen des nicht kleinzelligen Lungenkarzinoms (NSCLC):

Methodik Das Studienprotokoll sah vor, 92 erwachsene PatientInnen mit multiplen Hirnmetastasen bei NSCLC entweder mit WBRT alleine (RT) oder mit WBRT + TMZ 75 mg/m2 konkomitant zur Bestrahlung und nach 28 Tagen Pause 100 mg/m2, Tag 1–14/q28 (RCT) zu behandeln.

Ergebnisse Die Studie musste wegen fehlender Rekrutierung vorzeitig geschlossen werden. 35 PatientInnen wurden in die Studie aufgenommen, 22 in den RCT und 13 in den RT Arm. Die beobachteten Toxizitäten waren überwiegend auf TMZ zurückzuführen mit jeweils WHO Grade 3 und 4 Thrombocytopenie in 3/22 gegenüber 0/13, Leucocytopenie in 1/22 gegenüber 0/13 and Lymphocytopenie in 7/22 verglichen mit 12/13 PatientInnen im RCT Arm gegenüber dem RT Arm. Dreizehn PatientInnen des RCT Arms und sechs im RT Arm erreichten wegen systemischer Progression das erste Restaging zehn Wochen nach Therapiebeginn nicht. Die mediane Zeit bis zur Tumorprogression betrug 73 Tage (95 % CI: 63–80) im RCT Arm und 62 Tage im RT Arm, (95 % CI: 15–108), die mittlere Überlebenszeit 3 Monate in RCT (95 % CI: 1,7–3,1 Monate) gegenüber 6,3 Monate (95 % CI: 0,2–7,6 Monate) im RT Arm.

Schlussfolgerungen Diese Studie konnte ihr Rekrutierungsziel nicht erreichen. Wegen der zu geringen PatientInnenanzahl können auch keine Aussagen über die Wertigkeit der Zugabe von Temozolomide zur WBRT bei Hirnmetastasen von NSCLC gemacht werden.

Schlüsselwörter

Hirnmetastasen nicht kleinzelliges Bronchialkarzinom Ganzhirnbestrahlung Temozolomid Studiendesign 

Notes

Conflict of interest

All authors declare that they have no conflict interest including any financial, personal or other relationships with other people or organizations that could inappropriately influence this work.

References

  1. 1.
    Abrey LE, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol. 2001;53(3):259–65.PubMedCrossRefGoogle Scholar
  2. 2.
    Addeo R, et al. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for non-small cell lung cancer and breast cancer patients with brain metastases. Cancer. 2008;113(9):2524–31.PubMedCrossRefGoogle Scholar
  3. 3.
    Adonizio CS, et al. Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients. Clin Lung Cancer. 2002;3(4):254–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Antonadou D, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 2002;20(17):3644–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Athanassiou H, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005;23(10):2372–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Choong NW, et al. Phase II trial of temozolomide and irinotecan as second-line treatment for advanced non-small cell lung cancer. J Thorac Oncol. 2006;1(3):245–51.PubMedGoogle Scholar
  7. 7.
    Christodoulou C, et al. Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. J Neurooncol. 2005;71(1):61–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Cortot AB, et al. Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study. Ann Oncol. 2006;17(9):1412–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Dziadziuszko R, et al. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases. a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer. 2003;39(9):1271–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Kouroussis C, et al. Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study. Oncology. 2009;76(2):112–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Kouvaris JR, et al. Phase II study of temozolomide and concomitant whole-brain radiotherapy in patients with brain metastases from solid tumors. Onkologie. 2007;30(7):361–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Omuro AM, et al. Vinorelbine combined with a protracted course of temozolomide for recurrent brain metastases: a phase I trial. J Neurooncol. 2006;78(3):277–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Verger E, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys. 2005;61(1):185–91.PubMedCrossRefGoogle Scholar
  14. 14.
    Newton HB. Chemotherapy for the treatment of metastatic brain tumors. Expert Rev Anticancer Ther. 2002;2(5):495–506.PubMedCrossRefGoogle Scholar
  15. 15.
    Middlemas DS, et al. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res. 2000;6(3):998–1007.PubMedGoogle Scholar
  16. 16.
    Raymond E, et al. Activity of temozolomide against human tumor colony-forming units. Clin Cancer Res. 1997;3(10):1769–74.PubMedGoogle Scholar
  17. 17.
    Srivenugopal KS, et al. Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. Clin Cancer Res. 2001;7(5):1398–409.PubMedGoogle Scholar
  18. 18.
    Ridolfi R, et al. Temozolomide and interferon-alpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup. Melanoma Res. 2004;14(4):295–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Giorgio CG, et al. Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study. Lung cancer. 2005;50(2):247–54.Google Scholar
  20. 20.
    Ebert BL, et al. Use of temozolomide with other cytotoxic chemotherapy in the treatment of patients with recurrent brain metastases from lung cancer. Oncologist. 2003;8(1):69–75.PubMedCrossRefGoogle Scholar
  21. 21.
    Iwamoto FM, et al. A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol. 2008;87(1):85–90.PubMedCrossRefGoogle Scholar
  22. 22.
    Rivera E, et al. Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer. 2006;107(6):1348–54.PubMedCrossRefGoogle Scholar
  23. 23.
    Carlson BL, et al. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. Int J Radiat Oncol Biol Phys. 2009;75(1):212–9.PubMedCrossRefGoogle Scholar
  24. 24.
    van Nifterik KA, et al. Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys. 2007;69(4):1246–53.PubMedCrossRefGoogle Scholar
  25. 25.
    Macdonald DR, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277–80.PubMedGoogle Scholar
  26. 26.
    Trotti A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81.PubMedCrossRefGoogle Scholar
  27. 27.
    Addeo R, et al. Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer. 2007;7:18.PubMedCrossRefGoogle Scholar
  28. 28.
    Abrey LE, Mehta MP. Treatment of brain metastases: a short review of current therapies and the emerging role of temozolomide. Clin Adv Hematol Oncol. 2003;1(4):231–6.PubMedGoogle Scholar
  29. 29.
    Weller M. Chemotherapy for brain tumors in adult patients. Nervenarzt. 2008;79(2):231–41.PubMedCrossRefGoogle Scholar
  30. 30.
    Antonadou D, Coliarakis N, Paraskevaidis M, et al. A multiinstitutional trial comparing survival of patients with brain metastases from lung cancer treated with Temozolomide plus radiotherapy versus radiotherapy alone. Lung Cancer 2003;41 Suppl 2:42.Google Scholar

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  • Marco Ronald Hassler
    • 1
  • Wolfgang Pfeifer
    • 2
  • Thomas Hendrik Knocke-Abulesz
    • 3
  • Klaus Geissler
    • 4
  • Gabriele Altorjai
    • 5
  • Karin Dieckmann
    • 5
  • Christine Marosi
    • 1
    Email author
  1. 1.Department of Internal Medicine I, Clinical Division of OncologyMedical University of ViennaViennaAustria
  2. 2.Department PulmologyGeneral Hospital LinzLinzAustria
  3. 3.Department of RadiotherapyHospital HietzingViennaAustria
  4. 4.Department of Internal Medicine 5Hospital HietzingViennaAustria
  5. 5.Department of Radiotherapy and Radiobiology, Comprehensive Cancer Center-Central Nervous System Tumours Unit (CCC-CNS)Medical University ViennaViennaAustria

Personalised recommendations